Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant interleukin 21 (rIL-21) administered in combination with Rituxan (rituximab) in subjects with B-cell non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2008
At a glance
- Drugs Denenicokin; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors ZymoGenetics
- 31 Oct 2007 Status changed from recruiting to in progress.
- 11 Jul 2006 New trial record.